{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:16:58Z","timestamp":1770977818708,"version":"3.50.1"},"reference-count":33,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T00:00:00Z","timestamp":1468800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T00:00:00Z","timestamp":1468800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1111\/jcpt.12424","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T08:37:17Z","timestamp":1468831037000},"page":"546-551","source":"Crossref","is-referenced-by-count":26,"title":["Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia"],"prefix":"10.1155","volume":"41","author":[{"given":"B. A.","family":"Adeagbo","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry; Obafemi Awolowo University; Ile-Ife Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. O.","family":"Bolaji","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry; Obafemi Awolowo University; Ile-Ife Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. A.","family":"Olugbade","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry; Obafemi Awolowo University; Ile-Ife Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Durosinmi","sequence":"additional","affiliation":[{"name":"Department of Haematology & Immunology; Obafemi Awolowo University; Ile-Ife Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A.","family":"Bolarinwa","sequence":"additional","affiliation":[{"name":"Department of Haematology & Immunology; Obafemi Awolowo University; Ile-Ife Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Masimirembwa","sequence":"additional","affiliation":[{"name":"African Institute of Biomedical Science and Technology; Harare Zimbabwe"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2016,7,18]]},"reference":[{"key":"10.1111\/jcpt.12424-BIB0001|jcpt12424-cit-0001","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12424-BIB0002|jcpt12424-cit-0002","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1111\/jcpt.12424-BIB0003|jcpt12424-cit-0003","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukaemia: a sub analysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jcpt.12424-BIB0004|jcpt12424-cit-0004","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukaemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12424-BIB0005|jcpt12424-cit-0005","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1111\/jcpt.12424-BIB0006|jcpt12424-cit-0006","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene over expression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1111\/jcpt.12424-BIB0007|jcpt12424-cit-0007","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"10.1111\/jcpt.12424-BIB0008|jcpt12424-cit-0008","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4161\/cc.3.12.1331","article-title":"Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib","volume":"3","author":"Burger","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1111\/jcpt.12424-BIB0009|jcpt12424-cit-0009","first-page":"244","article-title":"Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with Chronic Myeloid Leukaemia","volume":"33","author":"Yamakawa","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1111\/jcpt.12424-BIB0010|jcpt12424-cit-0010","first-page":"781","article-title":"Analysis of CYP3A5*3 and CYP3A5*6 Gene Polymorphisms in Indian chronic myeloid leukemia patients","volume":"11","author":"Sailaja","year":"2011","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1111\/jcpt.12424-BIB0011|jcpt12424-cit-0011","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jcpt.12424-BIB0012|jcpt12424-cit-0012","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J Hum Genet"},{"key":"10.1111\/jcpt.12424-BIB0013|jcpt12424-cit-0013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cancergencyto.2005.01.015","article-title":"Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment","volume":"162","author":"Galimberti","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1111\/jcpt.12424-BIB0014|jcpt12424-cit-0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","article-title":"Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype","volume":"82","author":"Gurney","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12424-BIB0015|jcpt12424-cit-0015","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jcpt.12424-BIB0016|jcpt12424-cit-0016","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12424-BIB0017|jcpt12424-cit-0017","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00280-004-0931-x","article-title":"Single nucleotide polymorphisms modify the transporter activity of ABCG2","volume":"56","author":"Morisaki","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/jcpt.12424-BIB0018|jcpt12424-cit-0018","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","article-title":"Population pharmacokinetics and pharmacogenetics of imatinib in children and adults","volume":"14","author":"Petain","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jcpt.12424-BIB0019|jcpt12424-cit-0019","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1111\/jcpt.12424-BIB0020|jcpt12424-cit-0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1179\/1607845412Y.0000000067","article-title":"Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?","volume":"18","author":"Bedewy","year":"2013","journal-title":"Hematology"},{"key":"10.1111\/jcpt.12424-BIB0021|jcpt12424-cit-0021","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Network","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1111\/jcpt.12424-BIB0022|jcpt12424-cit-0022","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/10826076.2015.1025143","article-title":"Simple HPLC-UV Method for Pharmacokinetic Studies of Imatinib in the presence of common antimalarial agents","volume":"38","author":"Adeagbo","year":"2015","journal-title":"J Liq Chromatogr Relat Technol"},{"key":"10.1111\/jcpt.12424-BIB0023|jcpt12424-cit-0023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12424-BIB0024|jcpt12424-cit-0024","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/03602530801952617","article-title":"Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2)","volume":"40","author":"Gradhand","year":"2008","journal-title":"Drug Metab Rev"},{"key":"10.1111\/jcpt.12424-BIB0025|jcpt12424-cit-0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200104000-00005","article-title":"MDR1 Pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity","volume":"11","author":"Ameyaw","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1111\/jcpt.12424-BIB0026|jcpt12424-cit-0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2156-14-34","article-title":"Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa","volume":"14","author":"Bains","year":"2013","journal-title":"BMC Genet"},{"key":"10.1111\/jcpt.12424-BIB0027|jcpt12424-cit-0027","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1111\/jcpt.12424-BIB0028|jcpt12424-cit-0028","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.canlet.2005.06.051","article-title":"Implications of genetic polymorphisms in drug transporters for pharmacotherapy","volume":"234","author":"Kerb","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1111\/jcpt.12424-BIB0029|jcpt12424-cit-0029","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/jcpt.12424-BIB0030|jcpt12424-cit-0030","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1182\/blood-2010-07-296954","article-title":"Polymorphisms in the Multidrug Resistance gene MDR1(ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia (CML) receiving high dose imatinib","volume":"116","author":"Deenik","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jcpt.12424-BIB0031|jcpt12424-cit-0031","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia","volume":"28","author":"Ni","year":"2010","journal-title":"Med Oncol"},{"key":"10.1111\/jcpt.12424-BIB0032|jcpt12424-cit-0032","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukaemia patients receiving imatinib therapy","volume":"98","author":"Angelini","year":"2012","journal-title":"Haematologica"},{"key":"10.1111\/jcpt.12424-BIB0033|jcpt12424-cit-0033","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/clpt.2008.98","article-title":"Genetic variation in drug transporters in ethnic populations","volume":"84","author":"Cropp","year":"2008","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12424","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12424\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:01:58Z","timestamp":1671818518000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,18]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12424","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7,18]]}}}